Owner Investor / Financier Developer Technology licensor Technology / equipment supplier
Mitsui Chemicals, Inc. is a Japan-based global chemical manufacturer that develops and produces petrochemicals, basic chemicals, and a wide range of performance and specialty materials. Its portfolio spans polyolefins, phenols and intermediates, elastomers, engineering plastics, functional films and adhesives, nonwovens, ophthalmic lens monomers, agricultural materials, and other fine chemicals used in industrial and consumer applications.
The company serves markets including automotive and mobility, electronics and ICT, packaging, healthcare and medical, consumer goods, and agriculture. Mitsui Chemicals operates R&D and manufacturing sites across Japan, Asia, Europe, and the Americas, supported by regional subsidiaries such as Mitsui Chemicals Europe and Mitsui Chemicals America. The group also participates in joint ventures in key product areas and pursues technology development aimed at material efficiency, circularity, and lower environmental impact.
Also known as Mitsui Chemicals Europe GmbH, Mitsui Chemicals Europe, Mitsui Chemicals Group, Mitsui Chemicals America Inc., MCI and 4 more.
chemXplore tracks 7 projects involving Mitsui Chemicals, of which 3 are active.
Besides these 3, the record holds 3 completed projects and 1 cancelled.
Closest to start-up first.
The 4 that are completed, on hold or cancelled are in the record. See all 7 in chemXplore →
Adherent culture plate with high oxygen permeability, enhanced surface treatment, low autofluorescence and low drug adsorption to improve organoid culture and screening.
New ammonia-fired burners enabled a world-class 85% heat-input co‑firing rate in a test naphtha cracking furnace while keeping NOx comparable to current furnaces.
Acquisition closed early; PMI will integrate Ultradent and Kulzer, shift oral-care HQ to the US and target >$40M annual synergies by fiscal 2030.
Founding-member move ties chemical R&D to a 45+ partner network using CuspAI’s MIRA platform for end-to-end generative‑AI materials discovery.
Strong cash generation and higher earnings supported a proposed 10% dividend rise to €0.70/share; Bacalhau ramp-up and a €318m renewables purchase shaped the quarter.
New US holding will become the global headquarters for the group's oral care business after the Ultradent acquisition; establishment moved up to July 2026.
Acquire Ultradent to build a US dental materials platform, lift L&HC to ¥86bn by FY30 (ROS 17%), and capture whitening growth amid broader specialty-chemicals repositioning.
Acquiring Utah-based dental-products maker for $900M; will combine Ultradent with Kulzer, move oral-care HQ to the U.S., and target closing in Sept 2026.
active all projects
The 6 sharing the most projects, of 7.
